Applications of carbonic anhydrase inhibitors and activators in therapy

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 2, 2002, Pages 217-242

  Supuran, Claudiu T ^a   Scozzafava, Andrea ^a  

^a Studi di Firenze   (Italy)

Author keywords

Alzheimer's disease; Anticancer drug; Antiglaucoma agent; Carbonic anhydrase; Enzyme activator; Enzyme inhibitor; Isozyme; Sulfonamide; Tumour progression marker

Indexed keywords

1,3,4 THIADIAZOLE DERIVATIVE; ACETAZOLAMIDE; ALKYLATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOCHEMICAL MARKER; BRINZOLAMIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE ACTIVATOR; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE INHIBITOR; CYTOTOXIC AGENT; DICLOFENAMIDE; DORZOLAMIDE; ENZYME ACTIVATOR; ETHOXZOLAMIDE; INTERSTITIAL COLLAGENASE; ISOENZYME; LATANOPROST; MATRIX METALLOPROTEINASE INHIBITOR; METHAZOLAMIDE; MIOTIC AGENT; NUCLEOSIDE ANALOG; PILOCARPINE; PLACEBO; PLATINUM DERIVATIVE; POTASSIUM; SULFONAMIDE; TIMOLOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME ISOLATION; ENZYME MECHANISM; ENZYME STRUCTURE; GLAUCOMA; HUMAN; HUMAN CELL; HYPOKALEMIA; INTRAOCULAR PRESSURE; MEMORY; NEUROLOGIC DISEASE; NONHUMAN; OSTEOPOROSIS; PERIODIC PARALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RETINA MACULA CYSTOID EDEMA; REVIEW; TUMOR GROWTH; X RAY CRYSTALLOGRAPHY;

EID: 0036166662     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.2.217     Document Type: Review

References (90)

1. Carbonic anhydrase inhibitors and their therapeutic potential
2. Carbonic anhydrase inhibitors
3. Mechanism of cyanamide hydration catalyzed by carbonic anhydrase II suggested by cryogenic x-ray diffraction
4. Carbonic anhydrase III: The phosphatase activity is extrinsic
5. The sulfonamide group as an ideal anchor for the design of potent human carbonic anhydrase inhibitors: Role of hydrogen-bonding networks in ligand binding and drug design
6. Structure of the human carbonic anhydrase (hCA) isoenzyme I Michigan 1 variant in the absence and in the presence of exogenous zinc ions: The first CA binding two zinc ions
7. Keeping pace with a fast enzyme: Steps and missteps
8. 2 adduct of human carbonic anhydrase I Michigan 1
9. Fluoroaromatic-fluoroaromatic interactions between inhibitors bound in the crystal lattice of human carbonic anhydrase II
10. The catalytic properties of human carbonic anhydrase IX
11. Purification and kinetic analysis of recombinant CA XIII, a membrane carbonic anhydrase overexpressed in certain cancers
12. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells
13. Crystal structure of S-glutathiolated carbonic anhydrase III
14. Agents that target cysteine residues of biomolecules and their therapeutic potential
15. Mitochondrial carbonic anhydrase CA VB: Differences in tissue distribution and pattern of evolution from those of CA VA suggest distinct physiological roles
16. Nuclear NonO/p54(nrb) protein is a nonclassical carbonic anhydrase
17. 2 hydration
18. Crystal structure of the 'cab'-type beta class carbonic anhydrase from the archaeon Methanobacterium thermoautotrophicum
19. The active site architecture of Pisum sativum β-carbonic anhydrase is a mirror image of that of alpha-carbonic anhydrases
20. A closer look at the active site of gamma-class carbonic anhydrases: High-resolution crystallographic studies of the carbonic anhydrase from Methanosarcina thermophila
21. The active site structure of Thalassiosira weissflogii carbonic anhydrase 1
22. A biological function for cadmium in marine diatoms
23. Cloning, expression and some properties of α-carbonic anhydrase from Helicobacter pylori
24. Characterization of carbonic anhydrase from Neisseria gonorrhoeae
25. Crystal structure of E. coli β-carbonic anhydrase, an enzyme with an unusual pH-dependent activity
26. Characterisation of carbonic anhydrase in Plasmodium falciparum
27. 2H-Thieno[3,2-e]- and [2,3-e]-1,2-thiazine-6-sulfonamide 1,1-dioxides as ocular hypotensive agents: Synthesis, carbonic anhydrase inhibition and evaluation in the rabbit
28. Carbonic anhydrase inhibitors: Synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes
29. Carbonic anhydrase inhibitors: Synthesis of N-morpholythiocarbonylsulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozymes I, II and IV
30. Carbonic anhydrase inhibitors. Synthesis of topically effective intraocular pressure lowering agents derived from 5-(ω-aminoalkylcarboxamido)-1,3,4-thiadiazole-2-sulfonamide
31. Carbonic anhydrase inhibitors. Metal complexes of 5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide with topical intraocular pressure lowering properties: The influence of metal ions upon the pharmacological activity
32. Carbonic anhydrase inhibitors: Synthesis of sulfonamides incorporating 2,4,6-trisubstituted-pyridinium-ethylcarboxamido moieties possessing membrane-bound (CA IV) versus the cytosolic (CA I and CA II) isozymes
33. Carbonic anhydrase inhibitors: Sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions
34. Carbonic anhydrase inhibitors. Part 86. A QSAR study on some sulfonamide drugs which lower intra-ocular pressure, using the ACE non-linear statistical method
35. Carbonic anhydrase inhibitors: Inhibition of isozymes I, II and IV by sulfamide and sulfamic acid derivatives
36. Carbonic anhydrase inhibitors: Perfluoroalkyl/aryl-substituted derivatives of aromatic/ heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action
37. Carbonic anhydrase inhibitors: Water-soluble 4-sulfamoylphenylthioureas as topical intraocular pressure-lowering agents with long-lasting effects
38. Antifungal activity of Ag(I) and Zn(II) complexes of aminobenzolamide (5-sulfanilylamido-1,3,4-thiadiazole-2-sulfonamide) derivatives
39. Carbonic anhydrase inhibitors: Synthesis of Schiff bases of hydroxybenzaldehydes with aromatic sulfonamides and their reactions with arylsulfonyl isocyanates
40. Carbonic anhydrase inhibitors: Aromatic sulfonamides and disulfonamides act as efficient tumor growth inhibitors
41. Carbonic anhydrase inhibitors-Part 94. 1,3,4-thiadiazole-2-sulfonamidederivatives as antitumor agents?
42. Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents?
43. Carbonic anhydrase inhibitors: Synthesis of sulfonamides incorporating dtpa tails and of their zinc complexes with powerful topical antiglaucoma properties
44. Carbonic anhydrase inhibitors: Synthesis and inhibition against isozymes I, II and IV of topically acting antiglaucoma sulfonamides incorporating cis-5-norbornene-endo-3-carboxy-2-carboxamido moieties
45. Carbonic anhydrase inhibitors, interaction of boron derivatives with isozymes I and II: A new binding site for hydrophobic inhibitors at the entrance of the active site as shown by docking studies
46. Carbonic anhydrase inhibitors: 4-sulfamoyl-benzenecarboxamides and 4-chloro-3-sulfamoyl-benzenecarboxamides with strong topical antiglaucoma properties
47. Orbital symmetry in QSAR: Some Schiff's base inhibitors of carbonic anhydrase
48. Carbonic anhydrase and matrix metalloproteinase inhibitors: Sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient N-hydroxysulfonamides inhibit both these zinc enzymes
49. Matrix metalloproteinase inhibitors
50. Activation of carbonic anhydrase isozymes
51. Comparisons of intraocular-pressure-lowering efficacy and side effects of 2% dorzolamide and 1% brinzolamide
52. Topical dorzolamide 2%/timolol 0.5%: A review of its use in the treatment of open-angle glaucoma
53. Additive effect of latanoprost to the combination of timolol and dorzolamide
54. Changes in intraocular pressure associated with topical dorzolamide and oral methazolamide in glaucomatous dogs
55. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension
56. The role of carbonic anhydrase inhibitors in the management of macular edema
57. The roles of carbonic anhydrase isozymes in cancer
58. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro
59. Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumours
60. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer
61. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma
62. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: Correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix
63. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast
64. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis and microvessel density
65. Differential expression of cytoplasmic carbonic anhydrases, CA I and II and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and in colorectal tumors
66. Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors
67. The efficacy of acetazolamide on visual functions in a patient with choroid metastasis of breast carcinoma
68. Randomized trials of dichlorphenamide in the periodic paralyses
69. Pharmacologic treatment of essential tremor
70. Expression of membrane-associated carbonic anhydrase XIV on neurons and axons in mouse and human brain
71. Anticonvulsant activity of omeprazole in rats
72. +-ATP-ase and gastric mucosa carbonic anhydrase enzymes in humans
73. Preferential acetazolamide-induced vasodilation based on vessel size and organ: Confirmation of peripheral vasodilation with use of colored microspheres
74. Zinc deficiency and taste dysfunction; contribution of carbonic anhydrase, a zinc-metalloenzyme, to normal taste sensation
75. The identification of secreted carbonic anhydrase VI as a constitutive glycoprotein of human and rat milk
76. Elevated serum levels of antibodies to carbonic anhydrase I and II in patients with chronic pancreatitis
77. Glutathione oxidation by hypochlorous acid in endothelial cells produces glutathione sulfonamide as a major product but not glutathione disulfide
78. Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine
79. Carbonic anhydrase activators. Part 24. High affinity isozymes I, II and IV activators, derivatives of 4-(4-chlorophenylsulfonylureido-amino acyl)ethyl-1 H-imidazole
80. Carbonic anhydrase activators - Part 21. Novel activators of isozymes I, II and IV incorporating carboxamido and ureido histamine moieties
81. Carbonic anhydrase activators: Synthesis of high affinity isozymes I, II and IV activators, derivatives of 4-(4-tosylureido-amino acyl)ethyl-1h-imidazole (histamine derivatives)
82. Carbonic anhydrase activators: Synthesis of high affinity isozymes I, II and IV activators, derivatives of 4-(arylsulfonylureido-amino acyl)ethyl-1H-imidazole
83. Carbonic anhydrase activators: High affinity isozymes I, II and IV activators, incorporating a β-alanyl-histidine scaffold
84. Carbonic anhydrase activators: Design of high affinity isozymes I, II and IV activators, incorporating tri-/ tetrasubstituted-pyridinium-azole moieties
85. Structural and kinetic analysis of the chemical rescue of the proton transfer function of carbonic anhydrase II
86. Pharmacological enhancement of synaptic efficacy, spatial learning and memory through carbonic anhydrase activation in rats
87. A ternary complex of carbonic anhydrase: X-ray crystallographic structure of the adduct of human carbonic anhydrase II.with the activator phenylalanine and the inhibitor azide
88. Identification of the carbonic anhydrase II binding site in the Cl(-)/HCO(3)(-) anion exchanger AE1
89. Carbonic anhydrase activators: Human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1